Hexagon Nutrition Q4 FY26 Earnings Call Transcript Released
Hexagon Nutrition released its Q4 FY26 earnings call transcript. For FY26, revenue grew 17.8% to ₹382.63 crore. EBITDA increased 32.01% to ₹52.90 crore, with margins at 13.83%. PAT rose 56.1% to ₹37.94 crore. Management discussed business segments, growth drivers, and financial performance.
The release of the earnings call transcript and detailed financial results provides important information to investors about the company's performance and management's outlook, which can influence investment decisions.
The announcement is a release of a conference call transcript and financial results. While the results show positive growth, the nature of the announcement itself is informational and does not contain new strategic decisions or forward-looking guidance beyond what was discussed in the call.
Hexagon Nutrition Limited has released the transcript of its earnings conference call held on July 17, 2026, to discuss the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
The call featured management including Dr. Nikhil Kelkar (Joint Managing Director), Mr. Vikram Kelkar (Managing Director), and Mr. Soman Jana (Chief Financial Officer). They discussed the company's business, the global and Indian nutrition landscape, and the company's strategic focus on science-based nutrition solutions.
Key financial highlights for FY26 included a 17.8% year-on-year increase in revenue from operations to ₹382.63 crore, a 32.01% rise in EBITDA to ₹52.90 crore with margins expanding to 13.83%, and a 56.1% growth in Profit After Tax (PAT) to ₹37.94 crore. The company emphasized its diversified business model, strong manufacturing capabilities, and commitment to quality and innovation.
Discussions also covered the company's various business verticals: micronutrient premixes, therapeutic foods (like RUTF), clinical nutrition, food fortification, and consumer nutrition products. Management addressed questions regarding export revenue breakdown, raw material sourcing, product pipelines, demand in Tier 2/3 cities, and future growth drivers. They indicated expectations for margin expansion and improved capacity utilization, particularly driven by tenders and growing demand in the nutrition sector.
What to do with a filing like this
Hexagon Nutrition Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Hexagon Nutrition Limited. Read the original for the full detail.